Significantly higher salivary MLT levels were registered in OSCC patients than in healthy subjects. Till this day, not all sources of MLT in saliva are known. Potential synthesis inside the salivary glands has been hypothesized by several authors [34, 35]. The concentration of salivary MLT in healthy individuals varies from 1–5 pg/ml during daytime and from 10–50 pg/ml during nightime [30, 36]. Approximately 70% of serum MLT is partially bound to serum albumin [30, 36]. It is considered that only unbounded MLT enters the saliva by passive diffusion from serum to the salivary glands, where the MLT concentration reaches up to 33% of the value of MLT serum concentration [36]. Several papers revealed a receptor-dependant transport and storage of MLT inside the parotid glands [34, 37].
Studies on melatonin receptors 1A (MTNR1A) and squamous cell carcinomas in vitro had revealed diminished or even non-existent expression of these receptors due to DNA methylation [38]. Nakamura et al. have suggested MTNR1A as a target for epigenetic silencing at loci 4q35 which may present one of the key events in oral cancerogenesis [39]. In vitro, cessation of squamous cell carcinoma growth that lacked the expression of MTNR1A was achieved by exogenous restoration of MTNR1A receptors [39].
A possible explanation for elevated salivary MLT levels in OSCC patients could be the MLT receptors disorder in OSCC tissue and thereby the insensitivity of OSCC cells to MLT. This hypothesis could imply the protective direct effect of MLT on healthy oral mucosa, MLT overexpression, insensitivity or decreased expression of MTNR1A, but also the possibility of a yet unknown signal pathway. However, research on the expression of MLT receptors in vivo in OSCC tissue and clinically unchanged oral mucosa tissue in individuals with OSCC is called for to approve or disapprove these hypotheses.
Serum samples were taken to determine the relationship between the serum and salivary MLT levels in OSCC patients. Median ratios between MLT in UWS and serum MLT and MLT in SWS and serum MLT amounted to 23.66% and 13.15%, respectively. These results are consistent with the expected deviation between serum and salivary MLT levels in healthy individuals and do not support or disapprove the hypothesis of MLT synthesis in salivary glands. Serum MLT levels in healthy individuals start to increase between 6 and 8 p.m. and reach the highest values between midnight and 5 a.m., after which they begin to decrease significantly [31, 32]. Between 7 and 9 a.m. MLT levels in serum amount from 7 to 20 pg/ml [31, 32, 40, 41]. In this study, median of serum MLT in OSCC patients amounted 13.01 pg/ml (95% CI: 10.08–15.14). These results significantly differ from those obtained by Stanciu et al. in a study on serum MLT levels in OSCC patients [42]. This group of authors obtained high serum MLT levels at 7 a.m. in the healthy control group (median 47.6 pg/ml; interquartile range: 37.7–66.4; age 57 ± 7 years of age). The serum MLT values below 38.9 pg/ml sampled at 7 a.m. were furthermore identified as values with higher risk for OSCC incidence, with a specificity of 75% and sensitivity of 76.6%. Unfortunately, the authors did not explain or comment on the high MLT levels obtained in the healthy control group, which are inconsistent with other studies on MLT levels with healthy subjects older than fifty [31, 32] and rather correlate with the nocturnal levels of MLT in healthy subjects [40, 43–45].
Higher MLT values were registered in UWS than in SWS in both groups (Table 2) and thereby UWS could be considered as more representable for research on salivary MLT levels. We are unfamiliar with the reason for higher MLT levels obtained in UWS than in SWS, however it is established that over 65% of UWS is composed from the submandibular gland saliva and only 20% of the parotic saliva. Stimulated whole saliva is mostly composed from serous parotid gland saliva (> 50%) [46]. Therefore, we can hypothesize higher MLT concentrations in the submandibular than in the parotic saliva.
As expected, the PSQI was significantly higher in OSCC patients (U = 249.50, P = 0.0001). High PSQI did not correlate with serum and salivary MLT values, i.e. we expected lower MLT values in individuals with poor sleep quality, as is the case with some other malignancies [7–9]. The results of this study cannot justify or refute the exogenous MLT intake for sleep improvement.
Given that the salivary MLT concentrations were unknown in OSCC patients, it would not have been a mistake to include subjects with metastatic disease and not only T1N0M0 and T2N0M0 OSCC. However, stratification certainly contributed to the uniformity of this research and could pose potential relevance for future research on this topic. It would be intriguing to investigate MLT levels in patients with potentially malignant oral disorders and OSCC with and without metastatic disease.
ROC analysis was performed and found significant (P < 0.001) for the assessment of the MLT concentration limit in OSCC diagnosis. The area under the curve (AUC) amounted 0.84 and the sensitivity of 97.1% and specificity of 57.6% were obtained with an MLT concentration cut-off in the UWS of 0.83 (Youden index: 0.55). The results obtained with ROC analysis are even more representative than some of the presented cumulative biomarkers for OSCC, such as CEA (carcinoembryonic antigen), SCCA (squamous cell carcinoma antigen) and IAP (immunosuppressive acidic protein) [47].
Given the AUC value, salivary MLT could present a satisfactory diagnostic tool for OSCC as a tumour biomarker alone or in along with some other molecules, such as kininogen 1, cathepsin V, kallikrein 5 or matrix metalloproteinase 1 [48–50]. However, larger prospective studies are needed to evaluate the clinical use of MLT as an OSCC biomarker.
This study has several limitations. Due to the sample size, the correlation between alcohol consumption, smoking, particular systemic disease or a drug and the salivary MLT levels could not have been adequately assessed. Thereby, the aforementioned could represent potential confounders. Even though squamous cell carcinomas located on the tongue root, epiglottis or oropharynx were not included in this study, which are more commonly associated with HPV infection, unknown HPV status could present a confounder. The debate in literature on whether HPV infections have the same role in OSCC as in oropharyngeal squamous cell carcinoma is still active. PSQI questionnaire has its drawbacks, as does every survey: the inability to create a fully credible clinical picture, questionable credibility of the testimony and the recall bias.